Phuturdex › Diseases › Vulvar disease
Drugs in development · updated 13 November 2026
Vulvar disease: drugs in development
What it is
A vulvar disease is a particular abnormal, pathological condition that affects part or all of the vulva. Several pathologies are defined. Some can be prevented by vulvovaginal health maintenance.
Description not checked by Phuturdex: excerpt from the introduction of the article “Vulvar disease” on English Wikipedia, en.wikipedia.org · version of 10 May 2026 · licence CC BY-SA 4.0.
As of 13 November 2026 there are 37 active clinical trials (recruiting or ongoing, phases I–III) on 43 drugs for vulvar disease. 7 are experimental, that is not yet approved in the United States.
In Phuturdex every drug has its map of sites in Europe, every trial and its alerts, and you get an email when something changes. Full access free until 31 March 2027, no card needed.
Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Becotatug VedotinMRG003 | II | 1 | NCT07424664 |
| Cardunolizumab | II | 1 | NCT06292689 |
| Pudafensine | II | 1 | NCT07391241 |
| SCG142 | I–II | 1 | NCT06505551 |
| STAR0602 | I–II | 1 | NCT05592626 |
| YH32364 | I–II | 1 | NCT06975410 |
| ZimberelimabGLS-010, AB122 | II | 1 | NCT07424664 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ClotrimazoleClotic®, Trivagizole 3® | II–III | 1 | NCT06835361 |
| EstradiolESTRING, Vagifem | II–III | 1 | NCT07260825 |
| LactuloseChronulac®, Cephulac® | II–III | 1 | NCT06835361 |
| TestosteroneNatesto®, Vogelxo® | II–III | 1 | NCT07260825 |
| PembrolizumabKEYTRUDA, MK-3475 | II | 4 | NCT05903833 |
| CisplatinCis Platinum, Cisplatine | II | 3 | NCT04430699 |
| AldesleukinProleukin | I–II | 2 | NCT05639972 |
| BleomycinBleomicina, Blenoxane® | II | 2 | NCT06715592 |
| CyclophosphamideCyclophosphamid, Cytoxan | I–II | 2 | NCT06505551 |
| FludarabineFludara, FLUDARABIN | I–II | 2 | NCT06505551 |
| LenvatinibLenvatinb, Levatinib | II | 2 | NCT05903833 |
| NaltrexoneVivitrol®, Revia® | II | 2 | NCT07862400 |
| NivolumabONO-4538, Opdivo | II | 2 | NCT06638931 |
| ArtesunateArtesuante, Artesunate Amivas® | II | 1 | NCT06075264 |
| AtezolizumabTecentriq, Atezolizumb | I–II | 1 | NCT05000294 |
Sorted by most advanced phase and number of active trials. Showing 15 of 36 drugs.
Sites in Europe
32 sites of the active trials in 7 European countries, 28 recruiting.
- Germany15
- Netherlands6
- Spain4
- Italy3
- United Kingdom2
- France1
- Poland1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
All 43 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Vulvar neoplasm 31 drugs
- Uterine cervix neoplasm 214 drugs
- Vaginal neoplasm 17 drugs
- Anus neoplasm 27 drugs
- Penile neoplasm 26 drugs
- Metastasis 491 drugs
- Vulvodynia 5 drugs
- Endometrial neoplasm 299 drugs
- Ovarian neoplasm 420 drugs
- Biliary tract neoplasm 158 drugs
- Cholangiocarcinoma 132 drugs
- Bile duct neoplasm 35 drugs
Broader categories
- Female urogenital disease 1,195 drugs
- Female urogenital diseases and pregnancy complications 1,234 drugs
- Urogenital Diseases 1,543 drugs
- Infection 855 drugs
- DNA virus infectious disease 266 drugs
- Virus Diseases 531 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D014845 “Vulvar Diseases”.